MPs Demand Urgent NHS Overhaul for Weight-Loss Drug Rollout
“Plans to rollout Mounjaro are unambitious given the scale of the challenge,” the Commons’ health and social care committee stated in a report that warned current distribution strategies risk leaving millions of eligible patients behind. Influential members of Parliament called on NHS England to urgently reassess its phased rollout plan for glucagon-like peptide-1 receptor agonists (GLP-1s), citing severe capacity constraints and a heavy reliance on nursing staff.
The report, titled Food and Weight Management: Modernising obesity treatment, focuses on the high-demand medications used for weight loss and diabetes management. These include semaglutide (Wegovy), semaglutide (Ozempic and Rybelsus), tirzepatide (Mounjaro) and liraglutide. According to the committee, the present distribution framework—which requires appointments across general practitioner services, practice nurses, and healthcare assistants—will cost the health service billions while helping only a fraction of those who qualify.
Parliamentary Scrutiny Exposes Clinical Bottlenecks
The committee scrutinized NHS England’s phased rollout plan, which aims to deliver tirzepatide to 220,000 people over three years across three distinct cohorts. MPs calculated that this target reaches just 6% of the 2.8 million individuals currently eligible for the treatment. Furthermore, the existing care model requires approximately 21 appointments with a GP, four with practice nurses, and one healthcare assistant consultation per patient annually. Citing a 2025 data analysis by the King’s Fund, the report noted that maintaining this pathway would demand 700 million additional appointments each year, including 72.8 million more nurse consultations. This volume would add immense pressure to already stretched NHS services while driving up servicing costs estimated at £3.1bn.
Private Access and Emerging Black-Market Concerns
As NHS availability lags behind patient demand, frustrated individuals increasingly turn to private sources, according to evidence heard by the committee. This shift has created a two-tier system of access determined by an individual’s ability to pay rather than their clinical need. MPs warned that failing to provide equitable access will widen existing health disparities related to deprivation and inequality. The scarcity has also fueled an emerging black market for GLP-1 medications supplied by unregulated providers.
Committee Recommendations and Digital Alternatives
To alleviate the strain on frontline staff, the committee recommended that the government utilize digital providers and trusted online pharmacies as a more cost-effective alternative for prescribing the medications. Layla Moran, Liberal Democrat MP for Oxford West and Abingdon, who chairs the committee, criticized the current trajectory. “People can spend their entire lives battling with their weight,” Ms. Moran said. “We say the NHS should provide effective, structured support to beat obesity for all those who seek it. Instead, those people are repeatedly failed.” The committee urged the Department of Health and Social Care to hold a summit on GLP-1 access with a range of providers and healthcare professionals to open a dialogue on how best to improve the rollout.
Official Responses from Health Authorities
The committee noted: “We expect NHS integrated care boards to be making these drugs available as part of a phased rollout, starting with people in the greatest clinical need, while building the workforce and capacity needed to expand access safely and sustainably.”
Keep reading